TPST...$1.59...from the .90 range bottom...🥳BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.
georgie18
Member Level
Re: None
Friday, August 09, 2024 2:43:01 PM
Post#
652989
of 660804
TPST...$1.16...Taking a hit on earnings...adding more down here...🥳
Market Data 
Markets 
AI
